Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

48.84 1.49 +3.15%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Current ratio

Alert me on Current ratio

Septerna, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 5.0×, up 0.3× from fiscal 2025 (4.7×). That is in line with the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2025 4.7× (82.98%)
FY2024 27.8× 70.40%
FY2023 16.3× —

Quarterly newest first

Period Current ratio Change
Jun 2026 5.0× 6.07%
Mar 2026 4.7× (0.40%)
Dec 2025 4.7× (27.62%)
Sep 2025 6.5× (70.43%)
4 more quarters

Current ratio against peers

Company Current ratio
LKFT Lakefront Biotherapeutics - Sponsored ADR compare 32.8×
PVLA Palvella Therapeutics, Inc. compare 21.2×
IMNM Immunome, Inc. compare 15.1×
VERA Vera Therapeutics, Inc. compare 10.9×
ZYME Zymeworks Inc. compare 6.3×
AUPH Aurinia Pharmaceuticals Inc compare 6.1×
VCEL Vericel Corporation compare 5.1×
SEPN Septerna, Inc. 5.0×
BHVN Biohaven Ltd. compare 3.1×
Biotechnology industry median 4.9×
Healthcare sector median 3.1×
Market median 1.6×

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on SEPN